| From: archimedest | 7/12/2005 9:59:20 AM | | | | | | | Anyone have a target price? I am looking for a least a dollar but it may take a year or so. With this management team and advisory board, I am betting that they will have some deals with the big boys. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (4) |
|
| To: archimedest who wrote (5) | 7/12/2005 12:41:30 PM | | From: jmhollen | | | | No target price, but I think I'll join you in the Long department today or tomorrow.
Nano is definitely where it's at. Also, suggest you look at NNGY soon.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: archimedest who wrote (5) | 7/12/2005 3:14:03 PM | | From: donpat | | | | Re 'the big boys'
I agree!
First they must do the heavy thinking to perfect this development. Once they iron out the wrinkles with a few proofs of concept, I expect we will be trading well north of $1 if not north of $100.
I'm optimistic.
Nano is the future in so many ways.
Bio will be the foremost user, IMHO. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: canbballtrader | 7/13/2005 11:05:47 AM | | | | | | | News on financing is out. Convertible debentures. Looks like the company is on its way to legitimacy with a pending IND filing after the preclinical work. Does anyone know the amount of the financing? I would like to figure out the dilution impact via interest payments on shares. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: canbballtrader who wrote (9) | 7/13/2005 11:07:49 AM | | From: jmhollen | | | | NanoViricides Announces Terms of Series A Convertible Debentures and Receives Partial Funding
NEW YORK, Jul 13, 2005 (BUSINESS WIRE) -- NanoViricides, Inc. (Pink
Sheets:NNVC)(the "Company"), announced today the terms of its Series A
Convertible Debenture offered to select Institutional and Accredited Investors.
The Debentures are to be repaid on the first anniversary, with interest at the
rate of nine percent, which shall be paid quarterly in shares of the Company's
common stock equal to the average closing price for the preceding fifteen
trading days prior to the close of the respective quarterly period. The
principal balance of the Debentures may be repaid, at the holders' option, in
cash or a number of shares of common stock equal to seventy percent of the
average closing price of fifteen trading days prior to maturity (not to exceed
$.50 per share). The Company will have the right, but not the obligation, to
redeem the Debentures, if at maturity, the holders' conversion price is less
than $0.25 at the time of conversion. Any Debentures redeemed by the Company
shall be paid in immediately available funds with interest at the rate of
fifteen percent. If the Company registers any securities for public resale,
holders who purchased Debentures will have the right to include any shares of
common stock in the offering in such registration.
This press release does not constitute an offer or solicitation to sell or
purchase any of the Company's securities. Any of the Company's securities
offered will not be registered under the Securities Act of 1933, as amended (the
"Securities Act"), and may not be offered or sold in the United States unless
registered under the Securities Act upon applicable exemptions from registration
under the Securities Act.
Eugene Seymour, MD, CEO, said, "The financing, when completed, is anticipated to
be sufficient to allow the Company to complete its HIV drug Hivicide 1(TM)
preclinical work, and bring it to the point of applying for an IND with the Food
and Drug Administration."
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special
purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive
license in perpetuity for technologies developed by Theracour Pharma for the
five virus types - HIV, HCV, Herpes, Asian (bird) flu and Influenza. A
NanoViricide(TM) is a nanoparticle that contains an encapsulated active
pharmaceutical ingredient and targets it to a specific type of virus. When a
NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and
immobilizes circulating virus particles. Once this is done, the active
pharmaceutical ingredient is injected into the virus by the NanoViricide(TM)
particle, destroying it. The company plans to develop novel NanoViricide(TM)
drugs first against HIV, and anticipates that in 2006, it will license the
products to major pharmaceutical companies.
SOURCE: NanoViricides, Inc.
CONTACT: NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
or
Anil R. Diwan, Ph.D.
adiwan@snet.net
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (10) | 7/13/2005 11:24:54 AM | | From: jmhollen | | | | I hate freakin' Debentures, but this one doesn't come across as one of the Pangia-tyyle Death-Spiral screw jobs; and they can pay it off in advance if revenues are strong.
If someone reads it differently, please let me know.
John :-)
. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: donpat | 7/14/2005 11:47:35 AM | | | | | | Dr. John Rossi, Holder of 14 Key Patents, and Author of over 275 Scientific Articles, Joins NanoViricides, Inc. Scientific Advisory Board
Thursday July 14, 9:33 am ET
"Widely Regarded as a World Leader in Clinical Research for the Treatment of HIV/AIDS and in the Development of Therapeutic Applications of RNA Interference"
NEW YORK--(BUSINESS WIRE)--July 14, 2005-- NanoViricides, Inc. (Pink Sheets:NNVC - News), announced today that Dr. John Rossi, Chairman and Professor, Division of Molecular Biology, Beckman Research Institute and Dean, Graduate School of Biological Sciences, City of Hope National Medical Center, Duarte, CA
cityofhope.org
has joined the NanoViricides, Inc. Scientific Advisory Board.
City of Hope is a Comprehensive Cancer Center dedicated to the prevention and cure of cancer, HIV/AIDS, diabetes, and other life-threatening diseases.
"Dr. Rossi is a wonderful addition to our Scientific Advisory Board. He brings almost twenty five years of basic HIV research experience to our company. He is on the editorial boards of numerous science journals including Antisense Research and Development, Gene Therapy and Molecular Biology and Molecular Therapy, and has extensive experience in many critical areas that will help us develop true HIV killing nanomachines," said Eugene Seymour, MD, Chief Executive Officer of NanoViricides, Inc.
"Dr. Rossi has great expertise in the clinical aspects as well as in the HIV genome silencing aspects which are areas of special interest to NanoViricides. His active involvement as our scientific advisor will accelerate our development programs particularly for our second generation anti-HIV drugs and other nanoviricides," said Dr. Diwan, President of NanoViricides, Inc. and inventor of the underlying technology.
In addition to his responsibilities at the City of Hope, he is also Adjunct Professor, Division of Biomedical Sciences, University of California, Riverside, CA, as well as Adjunct Professor, Department of Biochemistry and Microbiology, Loma Linda University, CA.
Dr. Rossi received his PhD in microbial genetics from the University of Connecticut. His post-doctoral fellowship was at Brown University in Providence, RI.
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a nanoparticle that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus. When a NanoViricide(TM) drug particle enters the patient's blood stream, it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient is injected into the virus by the NanoViricide(TM) particle, destroying it. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that it will license the products to major pharmaceutical companies.
Contact:
NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
leo@nanoviricides.com
or
Anil R. Diwan, Ph.D.
adiwan@snet.net
Source: NanoViricides, Inc.
biz.yahoo.com |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: donpat | 7/17/2005 3:35:26 PM | | | | | | I wonder if A DNA 'tool' could be in NNVC's future:
Researchers turn DNA into a tool
By GREG KLINE
© 2005 THE NEWS-GAZETTE
Published Online July 17, 2005
Nature uses DNA molecules to store information. For example, about making proteins our body needs to function properly.
But University of Illinois researchers are using DNA in a different way - as a construction tool.
UI chemistry Professor Scott Silverman and colleagues employ the tendency of the ribbonlike DNA molecules to take a certain shape to control the shapes of other large macromolecules well over 100 atoms in size.
Moreover, they can tell going in whether the DNA will affect the shape of the target molecule to which they attach it.
"In order to use it we have to have a reasonably firm predictive ability," Silverman said recently.
Their method, published in the Journal of the American Chemical Society by Silverman and UI graduate student Chandrasekhar Miduturu, is the result of five years of work that will end up as Miduturu's doctoral dissertation. The work has been supported by the UI and the David and Lucile Packard Foundation.
At this point, the UI-developed technique is a good basic science tool for understanding how molecules such as DNA, RNA and proteins fold and take on structures, a process that's biologically essential and on the cutting edge of biotechnology.
"Here, we're trying to understand nature," Silverman said. "The utility of all this is still to be proven."
But if scientists can understand the process, they also may be able to use the tool to control it "in ways that could be potentially useful," he said.
"The shapes of molecules affect how they function," Silverman said. "By controlling the shape we have a way to control, eventually, the function."
At least some diseases are apparently rooted in breakdowns when molecules fold. The technique might, at some point in the future, be used to fix that, although Silverman thinks it's a stretch at this point to say it will lead to medical treatments.
Likewise, molecules often get together to create tiny molecular machines with various functions. The tool could be used to shape components in such machines and assemble them.
The technique might be useful in nanotechnology with
nonbiological macromolecules, as well, for instance the polymers that make up plastics.
"I think nonbiological applications are more likely," Silverman said. "But who knows what people are going to be able to come up with if we have control ... in such a detailed manner."
Other scientists have used DNA as a static "scaffold" on which to hang molecules in an array, typically two-dimensional.
But using it dynamically, and particularly with predictable results, to control the shape of individual molecules in three dimensions is a breakthrough for Silverman's lab, which emphasizes the study of nucleic acids like DNA and RNA.
RNA macromolecules, which the body uses to transform the information stored by DNA into things like proteins, are the test subject on which the UI researchers have applied DNA as a shape controller governed by chemical reactions.
To do that, they chemically attach two strands of DNA to an unfolded RNA molecule. The DNA strands resemble two sides of a ladder cut down the middle through its rungs. Those sides naturally join to create the classic "double helix" shape of DNA molecules.
The researchers then prompt the RNA molecule to fold as much as it can. The DNA, depending on its position, length and the chemistry used, either does nothing, like a barnacle stuck to a boat hull, or influences the structure of the RNA, Silverman said.
"Something's got to give, either the structure of the macromolecule or the DNA double helix," he said. "You can have cake. You can have ice cream. But you can't have both. We can predict and control" which.
Silverman and colleagues are working on attaching more than one DNA constraint to RNA and other large molecules, which might give them, in essence, two switches that could be turned on and off to orchestrate the folding process at various stages.
"That's some place that we'd like to go," Silverman said, "to see how much control we can have."
They also plan to work on shaping molecules in ways that could potentially allow them to assemble into molecular machines.
news-gazette.com
|
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
